BIO-PATH HOLDINGS, INC. (BPTH) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-03-20

Key Insights

Bio-Path Holdings has completed its domestication to Wyoming, creating a new class of Series S Preferred stock with 51 authorized shares that are convertible to common stock and hold 1% of the diluted voting power.
The company has appointed two new members, Wendy M. Charles, PhD and Michael Hickey, to its Scientific Advisory Board, bringing expertise in clinical research, regulatory compliance, and oncology drug development.
The new Scientific Advisory Board members were granted 100,000 stock options each with a three-year expiration and $0.06 exercise price, indicating the company's commitment to incentivizing and retaining its advisory talent.

Want the newest filings?

This analysis covers the filing from 2026-03-20. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-02-24

Bio-Path Holdings issued 51 shares of a new Series S Preferred stock and 2 million common stock warrants to its CEO's advisory firm, Steel Giants Advisors LLC, as payment for $10,000 in accrued consulting fees.
The company is undergoing a corporate domestication to move from Delaware to Wyoming, though the outcome and timing are uncertain.
Bio-Path is in discussions to restructure relationships with its payables and creditors, and intends to preserve drug supplies and seek shelf-life extensions, but success is not guaranteed.

Other reports for BIO-PATH HOLDINGS, INC.

Quarterly Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.